New hope for aggressive lymphoma: precision therapy trial launches

NCT ID NCT07499271

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of targeted drugs and chemotherapy in 35 people newly diagnosed with a specific, hard-to-treat form of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this precision approach can improve how long patients live without their cancer getting worse. Participants will receive a regimen including polatuzumab vedotin, rituximab, and standard chemotherapy drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone
What this could lead to: If successful, this could provide a more effective treatment option for a hard-to-treat form of lymphoma, potentially improving survival rates.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply broadly. The treatment involves chemotherapy drugs with known side effects like infection and heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.